| Dr Joseph Steele, MD | |
|
1414 W Fair Ave, Suite 36, Marquette, MI 49855-2675 | |
| (906) 361-6118 | |
| Not Available |
| Full Name | Dr Joseph Steele |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 11 Years |
| Location | 1414 W Fair Ave, Marquette, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306284005 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1306284005 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marquette General Hospital | Marquette, MI | Hospital |
| Munising Memorial Hospital | Munising, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apogee Medical Group Michigan Pc | 9931347879 | 35 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Entity Name | Northern Michigan Emergency Physicians, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417972183 PECOS PAC ID: 7113910399 Enrollment ID: O20040405000871 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Entity Name | Sound Inpatient Physicians-michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639311996 PECOS PAC ID: 5395896849 Enrollment ID: O20090624000252 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Entity Name | Dlp Marquette Physician Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487902995 PECOS PAC ID: 9931359601 Enrollment ID: O20121016000312 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Entity Name | Apogee Medical Group Michigan Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053655134 PECOS PAC ID: 9931347879 Enrollment ID: O20130604000688 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Entity Name | Adfinitas Health At Up Marquette, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205336260 PECOS PAC ID: 7315201480 Enrollment ID: O20180426001547 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Entity Name | Adfinitas Health Palliative Services, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639748734 PECOS PAC ID: 1355743584 Enrollment ID: O20210712001249 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Steele, MD 24792 Northwood Dr, Michigamme, MI 49861-9002 Ph: (906) 361-6118 | Dr Joseph Steele, MD 1414 W Fair Ave, Suite 36, Marquette, MI 49855-2675 Ph: (906) 361-6118 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."
A new study finds that factors known to increase the risk of breast cancer among white women have less influence in Hispanic women. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that research is needed to evaluate how breast cancer risk factors differ among ethnic and racial populations.
SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.
The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.
› Verified 7 days ago
Spring L Madosh, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 107 W Main St, Marquette, MI 49855 Phone: 906-225-3988 Fax: 906-225-4707 | |
Lyle J Vanderschaaf, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 420 W Magnetic St, Suite Er, Marquette, MI 49855 Phone: 888-674-0854 Fax: 906-225-3370 | |
Kathryn Lerche, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 W Fair Ave, Suite 36, Marquette, MI 49855 Phone: 906-225-3864 | |
Thomas Kates, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 W Fair Ave Ste 249, Marquette, MI 49855 Phone: 906-449-2900 Fax: 906-372-3230 | |
Dr. Cynthia K Lack, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 425 Fisher St, Marquette, MI 49855 Phone: 906-226-4618 Fax: 906-226-5317 | |
Siddhesh Ramesh Lotlikar, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 W Fair Avenue, Suite 36, Marquette, MI 49855 Phone: 906-225-3864 Fax: 906-225-3851 | |
Dr. Kayleen P Papin, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1401 Presque Isle Avenue, Health Center, Marquette, MI 49855 Phone: 906-227-2355 Fax: 906-227-2332 |